

Molecular Therapeutics of Cancer Research Conference -- 2017

Sponsored by the Cancer Molecular Therapeutics Research Association

The Hilton Hotel, Burlington, Vermont

Schedule and Program

IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers.

All scientific sessions will be at the Adirondack AB

Breaks, Poster sessions with refreshments will be at outside Adirondack ABCD

The opening reception Sunday evening will be at

The farewell reception will be on the Spirit of Ethan Allen, Lake Champlain

****Lodging will be in the Hilton Hotel, Burlington****

Meals will be in Adirondack CD

SUNDAY – JULY 16

4:00 pm	Arrival and check-in
6:00 – 7:00 pm	<i>Dinner</i>
7:30 – 7:45 pm	Welcome / Introductory Comments Peter Houghton, Greehey Children’s Cancer Research Institute, San Antonio, TX, President CMTRA
7:45 – 10:00 pm	EVENING SESSION: “GBM” Discussion Leader: Peter Houghton
7:45 – 8:00 pm	Introduction
8:00 – 8:30 pm	Steve Rosenfeld, Cleveland Clinic, Cleveland, OH “Targeting Invasion and Proliferation in Glioblastoma Through Molecular Motors”
8:30 – 8:55 pm	Discussion
9:00 – 9:30 pm	Shideng Bao, Cleveland Clinic, Cleveland, OH “Ubiquitination and Deubiquitination of c-Myc in Glioblastoma”
9:35 – 10:00 pm	Discussion
10:00 pm –	<i>Opening reception</i>

MONDAY – JULY 17

7:30 – 8:15 am	<i>Breakfast</i>
----------------	------------------

8:30 – 12:00 pm	MORNING SESSION: – “Microbiome and Cancer”
	Discussion Leader: Mary-Ann Bjornsti, University of Alabama at Birmingham, Birmingham, AL
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	Susan Erdman (MIT) (pending) “Gut Microbiota: Microbes Offer Engineering Strategies to Combat Cancer”
9:15 – 9:40 am	Discussion
9:40 – 10:00 am	Coffee Break
10:00 – 10:30 am	Lauren Oldfield, J. Craig Venter Institute, Washington DC “The Human Microbiome and Cancer”
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	Giorgio Trinchieri, NCI, Bethesda, MD “The Role of Microbiota in Cancer Therapy”
11:30 – 11:55 am	Discussion
12:00 – 1:00 pm	<i>Lunch</i>
2:00 – 4:30 pm	AFTERNOON SESSION: “Mechanisms of resistance to combination immunotherapy”
	Discussion Leader: Phillip Dennis, AstraZeneca
2:15 – 2:45 pm	Naiyer Rizvi, Columbia, New York, NY “Mutational Burden as a Predictive Feature for Response to Checkpoint Inhibitors”
2:45 – 3:10 pm	Discussion
3:15 – 3:45 pm	Patrick Hwu, University of Texas, MD Anderson Cancer Center, Houston, TX “Reciprocal Regulation of Immune Checkpoints as Mechanisms of Resistance to PD-1/PD-L1 Blockade”
3:45 – 4:10 pm	Discussion
4:30 – 6:00 pm	Poster Session and Social
6:00 – 7:00 pm	<i>Dinner</i>
7:30 – 9:45 pm	EVENING SESSION: “Complementary Technologies to De-risk Humanized Models in the Pre-Clinical Space”
	Discussion Leader: Robert Kramer
7:30 – 7:45 pm	Introduction

- 7:45 – 9:45 pm Karuppiah Kannan, Takeda Pharmaceuticals
 “Incorporating in vitro Tools to Better Identify and Validate Novel Targets During Pre-clinical Drug Development”
- Judy Lucas, Pfizer
 “How Syngeneic and Immune-oncology Mouse Models are Complementary to Humanized Models During the Drug Development Process”
- Brian Soper, Jackson Laboratory, Bar Harbor, ME
 “Utilization of Humanized NSG Mice to Better Evaluate Therapies in the Immune-oncology Space”
- Rajendra Kumari, Crown Bioscience UK
 “Tumor Heterogeneity and Immunotherapy Strategies”
- 9:45 pm – *Social*

TUESDAY JULY 18

- 7:30 – 8:15 am *Breakfast*
- 8:30 – 12:00 pm **MORNING SESSION: “Ubiquitination and Related Post-translational Modifications”**
- Discussion Leader: Stephanos Ioannidis, Forma Therapeutics, Watertown, MA
- 8:30 – 8:45 am Introduction
- 8:45 – 9:15 am Michael Clague, Liverpool University, UK
 “Biology of DUBs”
- 9:15 – 9:40 am Discussion
- 9:40 – 10:00 am *Coffee Break*
- 10:00 – 10:30 am Till Maurer, Genentech
 “USP7 Small Molecule Inhibitors Interfere with Ubiquitin Binding”
- 10:30 – 10:55 am Discussion
- 11:00 – 11:30 am Tauseef Butt, Progenra, Malvern, PA
 “Small Molecules as Frontline Therapy for Immune Oncology: Experience from Ubiquitin Pathway Targets”
- 11:30 – 11:55 am Discussion
- 12:00 – 1:00 pm *Lunch*
- 1:00 – 4:30 pm **OPEN NETWORKING AFTERNOON**
- 4:30 – 6:00 pm **Poster Session and Social**
- 6:00 – 7:00 pm *Dinner*

7:30 – 9:45 pm	EVENING SESSION: “New Technology Platforms”
	Discussion Leader: John Lazo, University of Virginia, Charlottesville, VA
7:30 – 7:45 pm	Introduction
7:45 – 8:15 pm	Nasim Annabi, Northeastern University, MIT, Boston, MA “Microengineered Biomaterials for Drug Discovery and Tissue Engineering”
8:15 – 8:40 pm	Discussion
8:45 – 9:15 pm	Jim Heath, California Institute of Technology, Pasadena, CA “Single-cell Analysis Tools for Cancer Drug Discovery”
9:15 – 9:40 pm	Discussion
9:45 pm –	<i>Social</i>

WEDNESDAY JULY 19

7:30 – 8:15 am	<i>Breakfast</i>
8:30 – 12:00 pm	MORNING SESSION: “Is Everything Druggable Now?”
	Discussion Leader: Alan Eastman, Dartmouth College, Hanover, NH
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	Eli Wallace, Peloton Therapeutics, Dallas, TX “Small Molecule HIF-2a Antagonists and Their Therapeutic Applications”
9:15 – 9:40 am	Discussion
9:40 – 10:00 am	Coffee Break
10:00 – 10:30 am	Michael White, Pfizer “Capitalizing on the Cacophony of the Molecular Etiology of Cancer”
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	Zhong-Yin Zhang, Purdue University, West Lafayette, IN “Therapeutic Potential of Targeting Protein Phosphatases”
11:30 – 11:55 am	Discussion
12:00 – 1:00 pm	Lunch
2:00 – 3:00 pm	ORAL PRESENTATIONS – Four Selected Presenters from the Posters

3:00 – 5:30 pm **AFTERNOON SESSION: “New Screening and Chemistry Library Strategies”**

Discussion Leader: Jim Winkler, Forma Therapeutics, Watertown, MA

3:00 – 3:15 pm Introduction

3:15 – 3:45 pm Rachel Grimly, AstraZeneca, Cambridge UK
“Hit Identification Strategies: a Vision for the Future”

3:45 -4:10 pm Discussion

4:10 – 4:40 pm John Cuozzo, X-Chem Pharmaceuticals, Waltham, MA
“The Power of Parallel Selections Using DNA-encoded Small Molecule Libraries”

4:45 – 5:10 pm Discussion

6:00 – 10:00 pm ***Farewell Reception – Spirit of Ethan Allen – Lake Champlain***

THURSDAY JULY 20

11:00 am CHECK OUT BY 11:00 AM

SPONSOR ACKNOWLEDGEMENTS

This meeting is co-sponsored by the Norris Cotton Cancer Center at Dartmouth, and the University of Vermont Cancer Center

This meeting would not be possible without the generous contributions from our many friends and colleagues:

**7 Hills Pharmaceuticals
Amgen
Janssen Research and Development
Pfizer**